Biotech Values

[pollyvonwog]

So this action applies to only 117,500 HCV patients.

So let's say ABBV discounts to $55k (just making this up) for ESRX, then those 117k patients are equivalent to roughly $6.5b in gauranteed revenue from V-Pak, yes? And that is before they add in any other PBMs and Euro GT1b sales... This looks pretty good for ENTA.